FDA issues warning over Kim Kardashian’s drug promotions

This is an archived article and the information in the article may be outdated. Please look at the time stamp on the story to see when it was last updated.

WASHINGTON — Reality TV star Kim Kardashian is no stranger to criticism, having spent the better part of the last decade in the public eye. But she’s probably never faced negative publicity like this before: The Food and Drug Administration says Kardashian’s social media posts violate drug-promotion rules.

Kardashian recently began promoting the drug Diclegis that treats morning sickness through her social media accounts.

Such endorsement deals are common for celebrities. In posts to Instagram earlier this month, Kardashian talks about her struggles with nausea due to pregnancy and recommends Diclegis.

Screen grab from Instagram

Screen grab from Instagram

But FDA regulators say the posts violate drug promotion rules because they don’t mention potentially dangerous side effects and drug interactions.

The drugmaker said in a statement Tuesday it will fix the problem.

Kardashian has removed the post from Instagram.

Notice: you are using an outdated browser. Microsoft does not recommend using IE as your default browser. Some features on this website, like video and images, might not work properly. For the best experience, please upgrade your browser.